Where to buy FOXO4-DRI (proxofim) in the UK: the sellers with a verifiable COA
The newest verifiable FOXO4-DRI certificate on any UK seller's website is on Xlpeptides (xlpeptides.com), analysed 13 Nov 2025 (task #88416 on Janoshik's site); 1 verified seller holds one covering FOXO4-DRI, listed newest first below. Of the 450 active UK sellers we audit, 38 (8%) publish their own verifiable Janoshik certificate of analysis, and this page lists which of them hold one covering FOXO4-DRI, newest certificate first. It is a record of paperwork, not a recommendation: The Peptide Watch sells nothing, takes no money from sellers and links to none of them. FOXO4-DRI is a synthetic peptide designed in Rotterdam to make senescent cells self-destruct, reported in a 2017 mouse study in Cell. A spin-out company holds the rights and it remains preclinical; no human has received it in a registered trial. Purity and identity cannot be judged by eye, so an independent certificate you can check is the only real proof of what is in the vial.
The one test that matters for FOXO4-DRI
Ignore the marketing. The question is simple: does the seller publish a verifiable Janoshik certificate that names the seller itself as the client? If it does, you can confirm an independent lab tested that batch. If it shows an in-house document, a borrowed certificate, or "COA on request", you cannot. Learn the two-minute check in how to verify a Janoshik COA.
Which UK sellers publish a verifiable COA
Of the 450 active UK research-peptide sellers we audit, only 38 (8%) publish their own verifiable Janoshik certificate. Any of them is where you can actually verify testing, for FOXO4-DRI or any compound. A few: Lab77Peptides · Peptology Labs · Biovanta · Camo Chem · Biohackpeptides · Zenic Labs. See the full independently-tested list, or check a specific shop's certificate with the free COA Checker.
Verified UK vendors with a confirmed FOXO4-DRI Janoshik certificate (1)
- Xlpeptides xlpeptides.com · newest FOXO4-DRI report 13 Nov 2025 · task #88416
Audit findings, not recommendations. Every entry is a report covering FOXO4-DRI that we opened on Janoshik's own site and that names the seller itself as the client; the date is the analysis date printed on the report where we have read it, otherwise the date the laboratory received the sample. The table below is the same ledger in full, so the two always agree. Not exhaustive: a vendor whose FOXO4-DRI report we have not yet read is not listed.
The one verifiable FOXO4-DRI certificate we have read
Each row was opened on Janoshik's own site by a real page load and transcribed. The client column is the name the laboratory printed; a certificate counts as a seller's own only when that name is the seller. The report date is the analysis date printed on the report where we have read it, otherwise the date the laboratory received the sample. The verify link opens the laboratory, never the shop. Audit findings, not recommendations.
| Seller | Task | Client on the report | Report date | Result | Batch | |
|---|---|---|---|---|---|---|
| Xlpeptides | #88416 | XL Peptides | 13 Nov 2025 | FOXO4-DRI · 12.02 mg · 99.149% | 250FOX | verify |
What the one FOXO4-DRI certificate shows
We have read one Janoshik report covering FOXO4-DRI, published by one UK seller. It was opened on Janoshik's own website and names the seller itself as the client. It is dated 13 Nov 2025.
One report gives a purity figure for FOXO4-DRI: 99.149%. A purity figure describes the sample the laboratory received, not every vial from that batch.
Read directly from the newest report: Xlpeptides: task #88416, sample received 13 Nov 2025, 12.02 mg recovered at 99.149%, client XL Peptides.
A certificate is a batch document. The lines that matter are the compound (it must say FOXO4-DRI, not only a batch code), the client (the shop, not its supplier) and the analysis date. A new batch is untested until a new report appears.
Questions people ask
Which UK sellers publish a verifiable Janoshik certificate naming FOXO4-DRI?
As of 4 October 2026, one: Xlpeptides. It has a report on Janoshik's own website that names the seller as the client and lists FOXO4-DRI. That is a statement about paperwork, not a recommendation; The Peptide Watch does not recommend anywhere to buy FOXO4-DRI.
How recent is the newest FOXO4-DRI certificate from a UK seller?
The newest we have read is Janoshik task #88416, sample received 13 Nov 2025. It is published by Xlpeptides and names it as the client. A certificate covers one batch, so an old one says little about stock on sale today.
How do I check that a certificate for FOXO4-DRI is genuine?
Four things: an independent laboratory is named; the client field names the seller you are buying from, not a supplier; the compound line says FOXO4-DRI; and the report's task number and key open the same report on the laboratory's own website (verify.janoshik.com). A branded PDF with no laboratory name and no verification code fails on the first check, however professional it looks. The free COA Checker on this site runs the checks for you.
Is FOXO4-DRI a licensed medicine in the UK?
Not a medicine anywhere. Sold as a research chemical. Preclinical. No registered trial and no human study. The Peptide Watch does not give legal or medical advice.
Why does The Peptide Watch not say where to buy FOXO4-DRI?
Because the site records paperwork, not recommendations. A verifiable certificate proves that a sample of one batch was tested. It does not prove the vial you receive matches it, and it says nothing about whether anyone should use FOXO4-DRI. Listing which sellers publish a certificate you can check, and which publish nothing, is as far as the evidence goes.
What the research shows for FOXO4-DRI, and what it does not
| Papers on PubMed | 19 |
|---|---|
| Indexed as rat or mouse studies | 7 |
| Indexed as clinical trials | 0 |
| Published since 2020 | 15 |
| Trials registered on ClinicalTrials.gov | 0 |
A 2017 mouse experiment. FOXO4-DRI is a peptide built from D-amino acids in reverse order, designed by Peter de Keizer's group at Erasmus University Medical Center in Rotterdam to stop the protein FOXO4 from holding p53 in senescent cells, so that those cells self-destruct. The 2017 paper in Cell reported restored fitness, fur density and kidney function in aged and fast-ageing mice. PubMed indexes 19 papers; there is no human study and ClinicalTrials.gov lists none.
Where development stands. Cleara Biotech was founded in Utrecht in 2018 to develop it and remains preclinical; the company's own history now describes work on next-generation compounds against the same FOXO4-p53 interaction rather than the original peptide. Nothing sold online is a trial drug.
What a certificate can tell you. One report, from XL Peptides in November 2025, recovered 12.02 mg at 99.149% purity on a 10 mg label.
Who owns FOXO4-DRI, and where it stands
| Originator | Peter de Keizer and colleagues, Erasmus University Medical Center, Rotterdam (Cell, 2017). |
|---|---|
| Rights | Cleara Biotech B.V., Utrecht, founded in 2018 on the underlying patents. |
| Development status | Preclinical. Preclinical. No registered trial and no human study. |
| Clinical trials | 0 registered on ClinicalTrials.gov |
| In the UK | Not a medicine anywhere. Sold as a research chemical. |
Counts are from PubMed on 15 September 2026 using the queries recorded in our evidence file; "clinical trial" is PubMed's own publication-type index. This is a description of the published record, not medical advice and not an argument for or against use.
Sources (4)
- Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. (Cell, 2017, PMID 28340339)
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes. (Front Bioeng Biotechnol, 2021, PMID 33996787)
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline. (Naunyn Schmiedebergs Arch Pharmacol, 2026, PMID 42024235)
- Cleara Biotech, company history
The Peptide Watch's position on FOXO4-DRI
Not a medicine anywhere. Sold as a research chemical. The Peptide Watch reads the certificates UK sellers publish and does not recommend anywhere to buy FOXO4-DRI. Sellers on this page are listed by the date of their newest FOXO4-DRI certificate and by nothing else. If you can verify a seller's testing, you can at least judge its evidence; if you cannot, you are taking the seller's word for what is in the vial. See how UK testing compares across every seller in the market statistics.
An honest note: a verifiable certificate proves a sample of a batch was tested, not that the specific vial you receive matches it, see what this can and can't tell you. The Peptide Watch sells no FOXO4-DRI and links to no shop; this is research-use-only information, not medical or dosing advice.
All peptides · Other compounds: BPC-157 · TB-500 · GHK-Cu · Ipamorelin · CJC-1295 · MOTS-c · Epithalon · Selank · Semax · Tesamorelin · Melanotan 2 · KPV · PT-141 · SS-31 · DSIP · NAD+ · Melanotan 1 · AOD-9604 · 5-Amino-1MQ · Glutathione · Kisspeptin · Thymosin Alpha-1 · GHRP-6 · HGH Fragment 176-191 · IGF-1 LR3 · Oxytocin · SLU-PP-332 · MK-677 · GLOW and KLOW blends · Sermorelin · GHRP-2 · Hexarelin · ARA-290 · AHK-Cu